Overview

in this video, Dr. Naiem T. Issa reviews Week 16 data from the ADvocate 1, ADvocate 2,
and ADhere studies, highlighting the efficacy of Ebglyss® (lebrikizumab) 250 mg Q2W
in improving atopic dermatitis in visible areas such as the hands and face, with or without
topical corticosteroids. He also presents a real-world case of a 40-year-old patient with
longstanding eczema, demonstrating marked improvements in BSA and itch severity
within 8 weeks of treatment with lebrikizumab.

This Class for

Clinical Pharmacy
Pharmacy
Physician
Resident / Fellow

What I will learn?

● Review Week 16 efficacy of lebrikizumab 250 mg Q2W in improving
atopic dermatitis on the hands and face.
● Highlight efficacy with and without topical corticosteroids.
● Demonstrate real-world effectiveness through a dupilumab-
refractory patient case with improvements in BSA and Itch NRS.
● Reinforce the key message: rapid, visible skin clearance with
lebrikizumab.

Disclaimer

This content is approved by Eli Lilly and Company (“Lilly”). This content is intellectual property of Lilly and its reproduction needs Lilly's prior permission
(This information/content is intended to Health Care Providers only)

For adverse events and safety reporting: email: [email protected]

24 /7 mobile: +966 567 868 843, Working hours Tel: +966 11 461 7800 , Ext: 1

For Lilly product information: email: [email protected]

For further information, please contact:

Eli Lilly and Company, Scientific Office P.O. Box 92120 Riyadh 11653, Kingdom of Saudi Arabia. Tel: +966 11 461 7800 Fax: +966 111 217 9900 email: [email protected]

PP-LK-SA-0265

Content